Published in J Virol on October 01, 1992
Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol (1995) 5.43
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol (1996) 3.82
Pervasive genomic recombination of HIV-1 in vivo. Genetics (2004) 2.79
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol (2002) 2.19
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Transition between stochastic evolution and deterministic evolution in the presence of selection: general theory and application to virology. Microbiol Mol Biol Rev (2001) 2.06
Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiologically linked individuals from Brazil. J Virol (1994) 2.05
Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay. J Virol (1997) 2.04
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev (2009) 2.02
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol (2001) 1.79
A double hairpin structure is necessary for the efficient encapsidation of spleen necrosis virus retroviral RNA. EMBO J (1994) 1.58
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus. J Virol (1999) 1.30
In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J Virol (2002) 1.27
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology (2004) 1.26
Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies. J Virol (2000) 1.21
Evolution of the human immunodeficiency virus envelope gene is dominated by purifying selection. Genetics (2006) 1.20
Genotypic prediction of HIV-1 subtype D tropism. Retrovirology (2011) 1.16
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol (1995) 1.06
Adaptation of human immunodeficiency virus type 1 to cells expressing a binding-deficient CD4 mutant (lysine 46 to aspartic acid). J Virol (1995) 1.03
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment. J Virol (1995) 1.02
The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains. J Virol (1997) 1.00
Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. J Virol (1998) 0.97
Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96
A direct demonstration of recombination between an injected virus and endogenous viral sequences, resulting in the generation of mink cell focus-inducing viruses in AKR mice. J Virol (1993) 0.94
Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol (2000) 0.93
Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B. Antimicrob Agents Chemother (2011) 0.92
Evolution of the human immunodeficiency virus type 1 subtype-specific V3 domain is confined to a sequence space with a fixed distance to the subtype consensus. J Virol (1997) 0.87
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Retrovirology (2012) 0.79
A diagnostic HIV-1 tropism system based on sequence relatedness. J Clin Microbiol (2014) 0.75
CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene (1988) 42.41
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Functional dissection of the HIV-1 Rev trans-activator--derivation of a trans-dominant repressor of Rev function. Cell (1989) 7.46
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell (1987) 4.84
Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science (1988) 4.63
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol (1991) 4.39
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol (1991) 4.37
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
Identification of the fusion peptide of primate immunodeficiency viruses. Science (1989) 3.83
Genetic recombination of human immunodeficiency virus. J Virol (1989) 3.61
Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57
Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol (1991) 3.07
Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol (1989) 2.89
Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. J Virol (1991) 2.77
Mutational analysis of the human immunodeficiency virus type 1 Rev transactivator: essential residues near the amino terminus. J Virol (1990) 2.36
Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell (1989) 2.33
Human immunodeficiency virus type 1 T-cell tropism is determined by events prior to provirus formation. J Virol (1990) 2.11
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site. J Virol (1991) 1.11
A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med (2001) 16.32
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 7.26
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
A new classification for HIV-1. Nature (1998) 5.30
Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill (2012) 4.96
Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol (2001) 4.90
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol (1992) 4.39
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS (1992) 3.91
Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med (1998) 3.84
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science (1993) 3.62
T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol (2000) 3.33
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Identification of two homologs of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in retroperitoneal fibromatosis of different macaque species. J Virol (1997) 2.91
In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci U S A (2000) 2.78
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
Influenza B virus in seals. Science (2000) 2.70
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50
Evolution of the V3 envelope domain in proviral sequences and isolates of human immunodeficiency virus type 1 during transition of the viral biological phenotype. J Virol (1992) 2.41
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35
HIV-1 infection requires a functional integrase NLS. Mol Cell (2001) 2.26
Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol (2000) 2.25
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol (1995) 2.24
Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. J Virol Methods (1993) 2.24
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology (1994) 2.15
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05
Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J Infect Dis (1993) 1.95
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet (1998) 1.88
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85
Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83
Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. J Clin Invest (1992) 1.81
Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol (1991) 1.80
Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol (1995) 1.79
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev (1994) 1.73
Measurement quality and validity of the "need for recovery scale". Occup Environ Med (2003) 1.70
Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol (1993) 1.70
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis (1999) 1.61
AIDS pathogenesis: a dynamic interaction between HIV and the immune system. Immunol Today (1990) 1.60
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS (1999) 1.55
T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today (1993) 1.54
Nocardiosis: a case series and a mini review of clinical and microbiological features. Neth J Med (2007) 1.54
Analysis of the junctions between human immunodeficiency virus type 1 proviral DNA and human DNA. J Virol (1990) 1.54
Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis (1996) 1.54
Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol (1999) 1.52
Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol (1998) 1.52
Influenza virus: a master of metamorphosis. J Infect (2000) 1.50
Single-dose antibiotic prophylaxis for urinary catheter removal does not reduce the risk of urinary tract infection in surgical patients: a randomized double-blind placebo-controlled trial. Clin Microbiol Infect (2011) 1.50
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (1992) 1.47
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS (2000) 1.47
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. J Infect Dis (1998) 1.46
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Catheter replacement in continuous arteriovenous hemodiafiltration: the balance between infectious and mechanical complications. Crit Care Med (2002) 1.44
Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS (1993) 1.44
Efficacy of the latest generation of antibody assays for (early) detection of HIV 1 and HIV 2 infection. Vox Sang (1989) 1.43
[Influenza pandemics: past and future]. Ned Tijdschr Geneeskd (1999) 1.42
Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J (1994) 1.41
In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J Infect Dis (1998) 1.40
Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol (1998) 1.39
Guiding outbreak management by the use of influenza A(H7Nx) virus sequence analysis. Euro Surveill (2013) 1.38